Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. During the same period in the previous year, the company posted ($0.28) EPS. Acumen Pharmaceuticals Stock Down 2.4 % Acumen Pharmaceuticals stock traded […]
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 699,400 shares, a growth of 53.6% from the December 31st total of 455,200 shares. Approximately 1.8% of the company’s stock are short sold. Based on an […]
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 159,800 shares, a decline of 26.3% from the April 30th total of 216,800 shares. Currently, 0.6% of the shares of the company are short sold. Based on […]
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) – Equities researchers at HC Wainwright issued their Q1 2023 earnings estimates for Acumen Pharmaceuticals in a report issued on Tuesday, March 28th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.31) per share for the quarter. HC Wainwright currently has a “Buy” rating and […]
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) issued its quarterly earnings results on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04), MarketWatch Earnings reports. Acumen Pharmaceuticals Stock Down 4.8 % NASDAQ ABOS opened at $4.01 on Wednesday. Acumen Pharmaceuticals has a 1-year low of […]